Haemonetics Stock Guidance

Comments

HAENYSE

Logo brought to you by Benzinga Data

Trade with Public

$78.82

-4.10-4.94%

At close: Jan 13, 4:00 PM EST

$78.78

-0.04-0.05%

After Hours: 4:08 PM EST

Vivasure Medical Limited was acquired by Haemonetics (HAE) on Friday, January 9, 2026

Overview News Earnings Options

Guidance

Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Haemonetics Stock Guidance | NYSE:HAE | Benzinga

Haemonetics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.

											Get Alert
11/06/2025	HAE	Haemonetics	FY	2026	$4.80	$5.00	$4.82	$1.26B	$1.30B	$1.30B	Get Alert
08/07/2025	HAE	Haemonetics	FY	2026	$4.70	$5.00	$4.88	$1.23B	$1.27B	$1.31B	Get Alert
05/08/2025	HAE	Haemonetics	FY	2026	$4.70	$5.00	$4.54	—	—	$1.36B	Get Alert
02/06/2025	HAE	Haemonetics	FY	2025	$4.50	$4.70	$4.59	$1.35B	$1.37B	$1.39B	Get Alert
11/07/2024	HAE	Haemonetics	FY	2025	$4.45	$4.75	$4.59	$1.38B	$1.41B	$1.40B	Get Alert
08/08/2024	HAE	Haemonetics	FY	2025	$4.45	$4.75	$4.60	$1.38B	$1.41B	$1.40B	Get Alert
05/09/2024	HAE	Haemonetics	FY	2025	$4.45	$4.75	$4.40	$1.38B	$1.41B	$1.37B	Get Alert
02/08/2024	HAE	Haemonetics	FY	2024	$3.90	$4.00	$3.89	$1.29B	$1.31B	$1.27B	Get Alert
12/12/2023	HAE	Haemonetics	FY	2024	$3.75	$3.95	$3.89	$1.26B	$1.29B	$1.27B	Get Alert
11/02/2023	HAE	Haemonetics	FY	2024	$3.75	$3.95	$3.81	$1.25B	$1.27B	$1.26B	Get Alert
08/08/2023	HAE	Haemonetics	FY	2024	$3.60	$3.90	$3.59	$1.24B	$1.27B	$1.24B	Get Alert
05/11/2023	HAE	Haemonetics	FY	2024	$3.45	$3.75	$3.40	$1.22B	$1.25B	$1.22B	Get Alert
02/07/2023	HAE	Haemonetics	FY	2023	$2.90	$3.00	$2.92	$1.14B	$1.16B	$1.14B	Get Alert
11/07/2022	HAE	Haemonetics	FY	2023	$2.70	$3.00	$2.79	$1.11B	$1.14B	$1.09B	Get Alert
08/10/2022	HAE	Haemonetics	FY	2023	$2.60	$2.90	$2.73	$1.07B	$1.10B	$1.06B	Get Alert
05/10/2022	HAE	Haemonetics	FY	2023	$2.50	$2.90	$2.75	$1.04B	$1.08B	$1.03B	Get Alert
02/08/2022	HAE	Haemonetics	FY	2022	$2.45	$2.55	$2.53	$974.92M	$992.33M	$996.92M	Get Alert

FAQ

What is the most recent guidance for Haemonetics (HAE)?

The most recent guidance for Haemonetics (HAE) was reported on November 6, 2025 for the full year 2026. The company provided earnings per share guidance in the range of $4.80 to $5.00, compared to the estimated EPS of $4.82. Additionally, Haemonetics forecasted revenue between $1.26B and $1.30B for the quarter.

Browse guidance and forecast on all stocks.